Robert Burns

H.C. Wainwright & Co.

Recent Articles

Biotech Receives First Approval; Drug Now Available 11/28/2023

Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results, noted H.C. Wainwright & Co. analysts Robert Burns and Dr. Raghuram Selvaraju.

Due to permission requirements, not all quotes are shown.